Effectiveness of Madopar HBS plus Madopar Standard in Patients with Fluctuating Parkinson’s Disease: Two Years of Follow-Up

Clinical response to a new galenic formulation of levodopa plus benserazide, Madopar HBS, was studied in 25 fluctuating parkinsonians. This open study was planned in two phases. In the first phase, th